Avatrombopag (Doptelet)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

Thrombopoietin receptor agonist

Diseases for which it is established

History of changes in FDA indication

History of changes in EMA indication

  • 6/20/2019: Initial authorization as Doptelet
  • Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
  • Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Also known as

  • Code names: E5501, YM477, AKR 501
  • Brand name: Doptelet